205 results on '"Lückerath, Katharina"'
Search Results
2. Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
3. Is There a Role of Artificial Intelligence in Preclinical Imaging?
4. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment
5. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
6. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study
7. Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance
8. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
9. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
10. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
11. Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
12. A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
13. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation
14. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation
15. Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
16. Data from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
17. Supplementary Figure S1 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
18. Supplementary Methods from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
19. Supplementary Table S1 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
20. Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
21. 18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men
22. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
23. PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study
24. CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents
25. Abstract 2635: Inhibiting deoxycytidine kinase significantly inhibits tumor growth in xenograft models of castration resistant prostate cancer
26. 18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men.
27. FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
28. Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
29. Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial Analysis
30. Nano-coating protects biofunctional materials
31. Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
32. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain
33. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
34. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma
35. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
36. Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
37. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
38. Imaging Inflammation with Positron Emission Tomography
39. PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
40. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
41. PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
42. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation
43. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
44. Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
45. A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
46. Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
47. Additional file 5: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
48. Additional file 4: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
49. Additional file 3: of Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
50. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.